[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.166.22. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 543
Citations 0
Correction
April 2016

Error in Table

JAMA Ophthalmol. 2016;134(4):469. doi:10.1001/jamaophthalmol.2016.0428

In the Original Investigation titled “Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema,” published online November 25, 2015, in JAMA Ophthalmology,1 there was an error in Table 3. The change in CST from baseline, mean (SD), µm for aflibercept (n = 61) should have read as follows: “−285 (147).” This article was corrected online.

References
1.
Wells  JA, Glassman  AR, Jampol  LM,  et al; Diabetic Retinopathy Clinical Research Network.  Association of baseline visual acuity and retinal thickness with 1-year efficacy of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema [published online November 25, 2015]. JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2015.4599.
PubMed
×